TABLE 3.

Evaluation of treatment response (n = 24)

	Imepitoin, n = 12	Placebo, n = 12	P value
Mean T1 (baseline) (±SD)	27.6 (±13.7)	16.8 (±10.8)	.004
Mean T2 (study phase) (±SD)	24.6 (±32)	4.2 (±3.5)	.01
Mean T2/T1 (± SD)	1.0 (±1.4)	0.4 (±0.4)	.37
Responder (T2/T1 ≥ 3)	2	0
Partial responder (T2/T1 > 1,5 and < 3)	1	0
Nonresponder (T2/T1 < 1,5)	9	12
Responder rate	17%	0%	.18

Note: Response to treatment was evaluated based on the prolongation of the head tremor‐free period, wherefore the quotient T2/T1 was calculated as the primary efficacy variable.

Abbreviations: T1, the longest interval (days) between 2 head tremor days during the 3‐month baseline period; T2: interval (days) between the second and the third head tremor day during study phase after completion of the titration phase.